Lättnad för Sobi: Nyförvärvad giktkandidat lyckas i fas III

I vintras köpte Sobi bioteknikbolaget Arthrosi i en miljardaffär, utan avgörande data på plats. Nu faller en klinisk pusselbit på plats. Färska fas III-resultat visar att giktkandidaten pozdeutinurad, en utpekad potentiell blockbuster, uppnår sitt primära effektmått.

By Lotta Naesenius

May 22, 2026 11:01 AM

I fas III-studien utvärderades pozdeutinurad (AR882) hos vuxna med gikt, inklusive okontrollerad gikt som inte kontrolleras tillräckligt med befintliga behandlingar.

Gikt orsakas av förhöjda urinsyranivåer i kroppen. Kandidaten pozdeutinurad är en hämmare av URAT1, ett protein som transporterar urinsyra tillbaka till blodet. Behandlingen tas som en tablett en gång dagligen och utvärderades i två olika doser, 50 mg och 75 mg.

1 month free trial

Get access to all content on Life Science Nordic

No commitment or card information required

Try Life Science Nordic now

Already a subscriber? Log In

Applies to personal subscription only.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.

Yes please, I would like to receive Life Science Nordics newsletter Read cookie and data policy.

Yes please, I would like to receive marketing, offers, surveys, etc. from Life Science Nordic Read cookie and data policy.

{{ window.visitor.corporateClient.name }}

Corporate solution

{{ window.visitor.ipAccess.corporateClient.name }}

{{ window.visitor.corporateClient.name }}

Lättnad för Sobi: Nyförvärvad giktkandidat lyckas i fas III

EMA opens review of Europe’s first potential Lyme disease vaccine

Phase III win for LSD‑based anxiety drug

EU approves Rinvoq for severe patchy hair loss

Lilly sues six companies over black market sales of experimental weight loss drug

Low-profile Danish biotech recruits Mikael Dolsten

Carola Lemne: “You only know afterwards whether you made the right choice”

100 000 timmar av beprövad tillförlitlighet: KNF:s membranpumpar sätter en ny standard

60 års expertis inom läcksökning: Pfeiffer Vacuum+Fab Solutions firar ett jubileum

From Complex Biology to Faster Decisions: Scalable 3D HCA for NAM-Driven Drug Discovery

QAdvis & Scandinavian CRO are now Aurevia

Experience fast and easy optical inspection

Strengthen your team with Clinical and Regulatory Experts

Clinical and regulatory expertise that delivers results

Medtech Compliance Forum by Aurevia & RAPS

Experienced clinical and regulatory support for a busy autumn

Expanding into the EU market?

Att välja rätt material för membranpumpen

Flexible clinical research support for your urgent project needs